μ-阿片系统在特应性皮炎表皮中的表达及作用初探

摘要/Abstract

摘要：

目的探讨μ-阿片系统在特应性皮炎表皮中的表达及其在发病中的作用。方法以特应性皮炎模型鼠为研究对象，分为阴性对照组、治疗前组、纳洛酮组、0.9%氯化钠溶液组4个组。采用荧光定量PCR法，对纳洛酮（μ-阿片受体拮抗剂）治疗前后小鼠表皮的μ-阿片受体及其配体β-内啡肽的mRNA的表达进行研究，同时对治疗前后小鼠皮损严重度评分及病理进行比较。结果特应性皮炎模型鼠在治疗前表皮的μ-阿片受体的表达较正常小鼠明显下调（t = 2.549，P < 0.05），经纳洛酮治疗后其μ-阿片受体的表达重新上调，与正常小鼠的表达差异无统计学意义（t = 0.671，P > 0.05）。表皮的β-内啡肽的表达在正常小鼠及特应性皮炎模型鼠的治疗前后差异均无统计学意义（P均 > 0.05）。经纳洛酮治疗后，特应性皮炎模型鼠的皮损严重度评分较治疗前明显下降（t = 8.338，P < 0.01），并与病理学改变一致。结论纳洛酮作为一种μ-阿片受体拮抗剂，对特应性皮炎具有一定疗效，能使特应性皮炎模型鼠表皮μ-阿片受体的表达恢复正常，证明μ-阿片系统与特应性皮炎的发病机制存在着一定关系。

关键词: 特应性皮炎, μ-阿片系统, 纳洛酮

Abstract:

Objective To investigate the expression of μ-opioid system in the epidermis of patients with atopic dermatitis and its role in the pathogenesis of atopic dermatitis. Methods Thirty-two mice were equally divided into 4 groups, negative control group, pre-treatment group, naloxone group, and physiological saline group. Ovalbumin was used to sensitize mice in pretreatment group, naloxone group, and physiological saline group for 7 weeks, then, mice in naloxone group and physiological saline group were treated with intracutaneous naloxone or physiological saline solution for 1 week, respectively. Mice were killed in negative control group and pre-treatment group at the end of sensitization, and in naloxone group and physiological saline group after 1-week injection with naloxone or physiological saline, skin tissues were obtained from the back of killed mice and subjected to histological examination with HE staining and quantitative fluorescent PCR for the detection of mRNA expression of μ-opioid receptor （MOR） and its ligand （β-endorphin） in epidermis. The atopic dermatitis severity index of lesions and histological changes were assessed before and after the treatment. Results In comparison with the negative control mice, the epidermal expression level of MOR was significantly decreased （t = 2.549, P < 0.05） in pre-treatment group, but increased in naloxone group and showed no statistical difference from the negative control group （t = 0.671, P > 0.05）. No significant difference was observed in the epidermal β-endorphin mRNA expression between negative control group and pre-treatment group or naloxone group （both P > 0.05）. The improvement of lesions could be visualized after treatment with naloxone （t = 8.338, P < 0.01）, which was concordant with the histological changes in naloxone group. Conclusions As an antagonist of MOR, naloxone can restore the expression of epidermal MOR in mice model for atopic dermatitis, and shows a certain efficacy in the treatment of atopic dermatitis, which proves that μ-opioid system is somewhat associated with the pathogenesis of atopic dermatitis.

Key words: atopic dermatitis, μ-opiate system, naloxone

陈洁石梅郭一峰姚志荣. μ-阿片系统在特应性皮炎表皮中的表达及作用初探[J]. 中华皮肤科杂志, 2010, 43(10): 709-712.

参考文献

参考文献 [1] Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatol 2005; 210: 91-99. [2] Nelde A, Teufel M, Hahn C, et al. The impact of the route and frequency of antigen exposure on the IgE response in allergy. Int Arch Allergy Immunol, 2001, 124(4); 461-469. [3] Spergel JM, Mizoguchi E, Brewer JP, et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest, 1998; 101: 1614-1622. [4] Herrick CA, Macleod H, Glusac E, et al. Th2 responses induced by epicutaneous of inhalational protein exposure are differentially dependent on IL-4. J Clin Invest, 2000; 105;765-775. [5] Stander S, Gunzer M, Metze D, et al. Localization of micro-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002; 110:75–83. [6] Bigliardi-Qi M, Bigliardi PL, Eberle AN, et al. Beta-endorphin stimulates cytokeratin 16 expression and downregulates muopiate receptor expression in human epidermis. J Invest Dermatol 2000; 114: 527–532. [7] Mitsutoshi Tominaga，Hideoki Ogawa，Kenji Takamori . Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228–2235. [8] Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatol 2004; 209: 183–189. [9] Mei Bigliardi-Qi, Claire Gaveriaux-Ruff, Katrin Pfaltz, et al. Deletion of μ- and κ-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol 2007; 127:1479-1488. [10] Paul L Bigliardi, Holger Stammer, Gerhard Jost, et al: Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56: 979-988. [11] Keith DE, Anton B, Murray SR, et al. μ-opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998; 53:377–384. [12] Georgala S, Schulpis KH, Papaconstantinou ED, et al: Raised beta-endorphin serum levels in children with atopic dermatitis and pruritus. J Dermatol Sci 1994; 8: 125–128. [13] Glinski W, Brodecka H, Glinska-Ferenz M, et al: Increased concentration of beta-endorphin in the sera of patients with severe atopic dermatitis. Acta Derm Venereol 1995; 75: 9–11.